The Journal of urology · 2026
Real-World Safety and Effectiveness of an Initial 0.1 mg Dose of Desmopressin in Older Men With Nocturnal Polyuria.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chu Cheng, Lin Chih-Chieh
Аннотация
PURPOSE: We investigated the safety and effectiveness of oral desmopressin tablet (starting dose 0.1 mg) in older Taiwanese men with nocturnal polyuria and nocturia and compared results in those aged ≥ 80 years vs < 80 years.
MATERIALS AND METHODS: Two hundred thirty-four Taiwanese men aged 60 years or older with nocturia (≥2 voids/night) and a nocturnal polyuria index of ≥ 33 were included. Patients received desmopressin 0.1 mg for up to 3 months. Effectiveness was evaluated at Month 1, and safety was assessed at Months 1, 2, and 3.
RESULTS: Two hundred eight patients (88.9%) aged 60 to 95 years provided follow-up data. Of the participants 70.1% completed the 3-month treatment period. Desmopressin was associated with significantly reduced median nocturnal voids/night (<80 years: -2.0; ≥80 years: -3.0) and urine volume (<80 years: -705 mL; ≥80 years: -660 mL) and increased hours of undisturbed sleep (<80 years: 1.0 hours; ≥80 years: 2.0 hours; all P < .001). In total, 39/234 (16.7%) discontinued desmopressin due to hyponatremia (determined through serum sodium monitoring). Twenty-eight patients with serum sodium decreases to ≤ 135 mmoL/L continued treatment for the full 3 months with appropriate dose adjustments.
CONCLUSIONS: This study provides real-world evidence of effectiveness and safety of oral desmopressin in an older Asian male population, including a subgroup aged older than 80 years. A starting dose of 0.1 mg oral desmopressin, coupled with careful serum sodium monitoring and dose adjustment if required, was associated with significant improvement in all nocturia parameters and a high rate of continuation.
MATERIALS AND METHODS: Two hundred thirty-four Taiwanese men aged 60 years or older with nocturia (≥2 voids/night) and a nocturnal polyuria index of ≥ 33 were included. Patients received desmopressin 0.1 mg for up to 3 months. Effectiveness was evaluated at Month 1, and safety was assessed at Months 1, 2, and 3.
RESULTS: Two hundred eight patients (88.9%) aged 60 to 95 years provided follow-up data. Of the participants 70.1% completed the 3-month treatment period. Desmopressin was associated with significantly reduced median nocturnal voids/night (<80 years: -2.0; ≥80 years: -3.0) and urine volume (<80 years: -705 mL; ≥80 years: -660 mL) and increased hours of undisturbed sleep (<80 years: 1.0 hours; ≥80 years: 2.0 hours; all P < .001). In total, 39/234 (16.7%) discontinued desmopressin due to hyponatremia (determined through serum sodium monitoring). Twenty-eight patients with serum sodium decreases to ≤ 135 mmoL/L continued treatment for the full 3 months with appropriate dose adjustments.
CONCLUSIONS: This study provides real-world evidence of effectiveness and safety of oral desmopressin in an older Asian male population, including a subgroup aged older than 80 years. A starting dose of 0.1 mg oral desmopressin, coupled with careful serum sodium monitoring and dose adjustment if required, was associated with significant improvement in all nocturia parameters and a high rate of continuation.